ABL Bio Inc. (Kosdaq: 298380) is a South Korean biotechnology company dedicated to the development of bispecific antibody therapeutics to improve and save people's lives. With our BsAb platforms ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B,’ we have built a robust pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated excellent efficacy and safety. We also created a next-generation antibody drug conjugate program to treat various cancers. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. We continue to actively expand and advance our pipeline through global strategic partnerships. For more information, please visit http://ablbio.com
2 signals in the last 90 days.
The order this company entered each market — oldest to newest
ABL Bio Seeks Clinical Trial Approval
ABL Bio invests additional 37.7 billion won in NEOK Bio
Sign up to see the full signal feed
How ABL Bio Inc.'s international expansion compares to its competitors
ABL Bio Inc.YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 ABL Bio Inc.You | 1 | 0 | 0% | 2 | 53 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
A new book analyzes drug development as an industrial battlefield involving capital, technology, and business strategy, covering obesity, cancer, immune, and brain disease treatments with global pharmaceutical competition.
ABL Bio presented bispecific ADC candidates ABL206 and ABL209 at AACR 2026, receiving FDA IND approval for Phase 1 trials. The company plans to transition to dual-payload ADC strategy next year.
Korean biopharma companies increasingly adopt NewCo models to secure global funding and development expertise, but success depends on strategic design and actual value creation, not just entity formation.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about ABL Bio Inc.'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
